Rapid onset of efficacy of rasagiline in early Parkinson's disease

Neurological Sciences

Volumn 34, Issue 11, 2013, Pages 2007-2013

  Zambito Marsala, Sandro ^a   Vitaliani, Roberta ^b   Volpe, Daniele ^c   Capozzoli, Francesca ^d   Baroni, Luciana ^e   Belgrado, Enrico ^f   Borsato, Carlo ^g   Gioulis, Manuela ^a   Marchini, Corrado ^a   Antonini, Angelo ^h  

^a SAN MARTINO HOSPITAL   (Italy)

^b CA FONCELLO HOSPITAL   (Italy)

^c Fatebenefratelli Hospital   (Italy)

^d S MARIA DEGLI ANGELI HOSPITAL   (Italy)

^e Ospedale Villa Salus   (Italy)

^f SANTA MARIA DELLA MISERICORDIA UNIVERSITY HOSPITAL   (Italy)

^g Piove di Sacco Hospital   (Italy)

^h IRCCS SAN CAMILLO HOSPITAL   (Italy)

Author keywords

Early improvement; Motor symptoms; Rasagiline

Indexed keywords

RASAGILINE;

ADD ON THERAPY; AGED; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; FEMALE; HOEHN AND YAHR SCALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PARKINSON DISEASE; SINGLE BLIND PROCEDURE; TREATMENT OUTCOME; UNIFIED PARKINSON DISEASE RATING SCALE;

AGED; ANTIPARKINSON AGENTS; FEMALE; HUMANS; INDANS; MALE; MONOAMINE OXIDASE INHIBITORS; PARKINSON DISEASE; SINGLE-BLIND METHOD; TREATMENT OUTCOME;

EID: 84888308140     PISSN: 15901874     EISSN: 15903478     Source Type: Journal    
DOI: 10.1007/s10072-013-1437-2     Document Type: Article

References (17)

1. Jann MW (2011) Advanced strategies for treatment of Parkinson's disease: the role of early treatment. Am J Manag Care 17(Suppl 12):S315-S321
2. Hauser RA (2010) Early pharmacologic treatment in Parkinson's disease. Am J Manag Care 16(Suppl Implications):S100-S107
3. Tsouli S, Konitsiotis S (2010) How should we treat a patient with early Parkinson's disease? Int J Clin Pract 64(9):1210-1219
4. Hoy SM, Keating GM (2012) Rasagiline: a review of its use in the treatment of idiopathic Parkinson's disease. Drugs 72(5):643-669
5. Rascol O, Brooks DJ, Melamed E, Oertel W, Poewe W, Stocchi F et al (2005) Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in adjunct therapy with rasagiline given once daily, study): a randomised, double-blind, parallel-group trial. Lancet 365(9463):947-954
6. Parkinson study group (2005) A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 62(2):241-248
7. Parkinson study group (2002) A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study. Arch Neurol 59(12):1937-1943
8. Hauser RA, Lew MF, Hurtig HI, Ondo WG, Wojcieszek J, Fitzer-Attas CJ (2009) TEMPO open-label study group. Long-term outcome of early versus delayed rasagiline treatment in early Parkinson's disease. Mov Disord 24(4):564-573
9. Olanow CW, Rascol O, Hauser R, Feigin PD, Jankovic J, Lang A et al (2009) A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N Engl J Med 361(13):1268-1278
10. Wilson RE, Seeberger LC, Silver D, Griffith A, Conner JB, Salzman PM (2011) LEGATO investigators. Rasagiline: time to onset of antiparkinson effect is similar when used as a monotherapy or adjunct treatment. Neurologist 17(6):318-324
11. Fahn S, Elton R (1987) Unified Parkinson's disease rating scale. In: Fahn S, Marsden CD, Goldstein M, Calne DB (eds) Recent developments in Parkinson's disease, vol 2. Macmillan, New York, pp 153-163
12. Hoehn MM, Yahr MD (1967) Parkinsonism: onset, progression, and mortality. Neurology 17:427-442
13. Perez-Lloret S, Rascol O (2011) Safety of rasagiline for the treatment of Parkinson's disease. Expert Opin Drug Saf 10(4):633-643
14. Fahn S, Oakes D, Shoulson I, Kieburtz K, Rudolph A, Lang A et al (2004) Levodopa and the progression of Parkinson's disease. N Engl J Med 351(24):2498-2508
15. Chahine LM, Stern MB (2011) Rasagiline in Parkinson's disease. Int Rev Neurobiol 100:151-168
16. Goetz CG, Schwid SR, Eberly, Oakes D, Shoulson I (2006) Parkinson study group TEMPO and PRESTO investigators. Safety of rasagiline in elderly patients with Parkinson disease. Neurology 66(9):1427-1429
17. Tarrants ML, Denarié MF, Castelli-Haley J, Millard J, Zhang D (2010) Drug therapies for Parkinson's disease: a database analysis of patient compliance and persistence. Am J Geriatr Pharmacother 8(4):374-383